Document:

Exhibit 4.3

 

EXHIBIT B

 

FORM OF ORDINARY SHARES PURCHASE WARRANT

 

NEITHER THE ISSUANCE
AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY
ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID
ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR
FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

	 	Right to Purchase such Number of Ordinary Shares of Todos Medical Ltd. as to be Determined (subject to adjustment as provided herein)

 

ORDINARY SHARES PURCHASE WARRANT

 

	No. 2019-00__	Issue Date: February ___, 2019

 

TODOS MEDICAL LTD.,
a corporation organized under the laws of the State of Israel (the “Company”), hereby certifies that, for value received,
___________, or its assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the
Company at any time commencing six (6) months after the Determination Date until 5:00 p.m. E.S.T. on the third (3rd)
anniversary of the Determination Date (the “Expiration Date”), up to such number of Ordinary Shares of the Company
as to be determined pursuant to Section 4 of Convertible Loan Agreement (the “Convertible Loan Agreement”), dated as
of February 27, 2019, entered into by the Company and the Holder, fully paid and nonassessable Ordinary Shares of the Company at
a per share purchase price as to be determined pursuant to Section 4 of Convertible Loan Agreement. The purchase price per share,
as adjusted from time to time as herein provided, is referred to herein as the “Purchase Price.” The number and character
of such Ordinary Shares and the Purchase Price are subject to adjustment as provided herein. Capitalized terms used and not otherwise
defined herein shall have the meanings set forth in the Convertible Loan Agreement.

 

As used herein the
following terms, unless the context otherwise requires, have the following respective meanings:

 

(a) The term “Company”
shall include Todos Medical Ltd. and any corporation which shall succeed or assume the obligations of Todos Medical Ltd. hereunder.

 

(b) The term “Determination
Date” means the date on which the number of Warrant Shares and the Purchase Price are determined pursuant to Section 4 of
the Convertible Loan Agreement.

 

(c) The term “Ordinary
Shares” includes (a) the Company’s Ordinary Shares, NIS 0.01 par value per share, as authorized on the date of the Convertible
Note Agreement, and (b) any other securities into which or for which any of the securities described in (a) may be converted
or exchanged pursuant to a plan of recapitalization, reorganization, merger, sale of assets or otherwise.

 

     

     

    

 

(d) The term “Other
Securities” refers to any stock (other than Ordinary Shares) and other securities of the Company or any other person (corporate
or otherwise) which the holder of the Warrant at any time shall be entitled to receive, or shall have received, on the exercise
of the Warrant, in lieu of or in addition to Ordinary Shares, or which at any time shall be issuable or shall have been issued
in exchange for or in replacement of Ordinary Shares or Other Securities pursuant to Section 3 or otherwise.

 

(e) The term “Warrant
Shares” shall mean the Ordinary Shares issuable upon exercise of this Warrant.

 

1. Exercise of Warrant.

 

1.1. Number of Shares
Issuable upon Exercise. From and after the Determination Date through and including the Expiration Date, the Holder hereof
shall be entitled to receive, upon exercise of this Warrant in whole in accordance with the terms of subsection 1.2 or upon
exercise of this Warrant in part in accordance with subsection 1.3, Ordinary Shares of the Company, subject to adjustment
pursuant to Section 3.

 

1.2. Full Exercise.
This Warrant may be exercised in full by the Holder hereof by delivery of an original, pdf copy via electronic mail or facsimile
copy of the form of subscription attached as Exhibit A hereto (the “Subscription Form”) duly executed by
such Holder, and on a cash-basis by delivery within two days thereafter of payment, either in cash, by wire transfer, or by certified
or official bank check payable to the order of the Company, in the amount obtained by multiplying the number of Ordinary Shares
for which this Warrant is then exercisable by the Purchase Price then in effect (as may be adjusted to reflect any adjustment in
the total number of Ordinary Shares issuable to the Holder per the terms of this Warrant), or on a cashless basis as provided for
in Section 2 below. The original Warrant is not required to be surrendered to the Company until it has been fully exercised.

 

1.3. Partial Exercise.
This Warrant may be exercised in part (but not for a fractional share) by delivery of a Subscription Form in the manner and at
the place provided in subsection 1.2, either on a cashless basis or on a cash-basis, except that the amount payable by the
Holder on such partial exercise shall be the amount obtained by multiplying (a) the number of whole Ordinary Shares designated
by the Holder in the Subscription Form by (b) the Purchase Price then in effect. On any such partial exercise the Holder may
surrender the original Warrant, and the Company, at its expense, will forthwith issue and deliver to or upon the order of the Holder
hereof a new Warrant of like tenor, in the name of the Holder hereof or as such Holder (upon payment by such Holder of any applicable
transfer taxes) may request, the whole number of Ordinary Shares for which such Warrant may still be exercised for the balance
of.

 

1.4. Fair Market Value.
Fair Market Value of an Ordinary Share as of a particular date (the “FMV Date”) shall mean:

 

(a) If the Company’s
Ordinary Shares are traded on an exchange or is quoted on the NASDAQ Global Market, Nasdaq Global Select Market, the NASDAQ Capital
Market, the New York Stock Exchange or the American Stock Exchange, LLC, then the average of the closing or last prices, respectively,
reported for the ten trading days immediately preceding the FMV Date, as quoted by Bloomberg, LP;

 

(b) If the Company’s
Ordinary Shares are not traded on an exchange or on the NASDAQ Global Market, Nasdaq Global Select Market, the NASDAQ Capital Market,
the New York Stock Exchange or the American Stock Exchange, LLC, but is traded in the over-the-counter market, then the average
of the closing bid price reported for the ten trading days immediately preceding the FMV Date, as quoted by Bloomberg, LP;

 

    	 	2	 

     

    

 

(c) Except as provided
in clause (d) below and Section 2.1, if the Company’s Ordinary Shares are not publicly traded, then as the Holder and the
Company agree, or in the absence of such an agreement, by arbitration in accordance with the rules then standing of the American
Arbitration Association, before a single arbitrator to be chosen from a panel of persons qualified by education and training to
pass on the matter to be decided; or

 

(d) If the FMV Date
is the date of a liquidation, dissolution or winding up, or any event deemed to be a liquidation, dissolution or winding up pursuant
to the Company’s Articles of Association, then all amounts to be payable per share to holders of the Ordinary Shares pursuant to
the Articles of Association in the event of such liquidation, dissolution or winding up, plus all other amounts to be payable per
share in respect of the Ordinary Shares in liquidation under the Articles of Association, assuming for the purposes of this clause
(d) that all of the Ordinary Shares then issuable upon exercise of all of the Warrants are outstanding at the FMV Date.

 

1.5. Company Acknowledgment.
The Company will, at the time of the exercise of the Warrant, upon the request of the Holder hereof acknowledge in writing its
continuing obligation to afford to such Holder any rights to which such Holder shall continue to be entitled after such exercise
in accordance with the provisions of this Warrant. If the Holder shall fail to make any such request, such failure shall not affect
the continuing obligation of the Company to afford to such Holder any such rights.

 

1.6. Trustee for Warrant
Holders. In the event that a bank or trust company shall have been appointed as trustee for the Holder of the Warrants pursuant
to Subsection 3.2, such bank or trust company shall have all the powers and duties of a warrant agent (as hereinafter described)
and shall accept, in its own name for the account of the Company or such successor person as may be entitled thereto, all amounts
otherwise payable to the Company or such successor, as the case may be, on exercise of this Warrant pursuant to this Section 1.

 

1.7 Delivery of
Stock Certificates, etc. on Exercise. The Company agrees that the Ordinary Shares purchased upon exercise of this Warrant shall
be deemed to be issued to the Holder hereof as the record owner of such shares as of the close of business on the date on which
delivery of a Subscription Form shall have occurred and payment made for such shares as aforesaid. As soon as practicable after
the exercise of this Warrant in full or in part, and in any event within three (3) business days thereafter (“Warrant Share
Delivery Date”), the Company at its expense (including the payment by it of any applicable issue taxes) will cause to be
issued in the name of and delivered to the Holder hereof, or as such Holder (upon payment by such Holder of any applicable transfer
taxes) may direct in compliance with applicable securities laws, a certificate or certificates for the number of duly and validly
issued, fully paid and non-assessable Ordinary Shares (or Other Securities) to which such Holder shall be entitled on such exercise,
plus, in lieu of any fractional share to which such Holder would otherwise be entitled, cash equal to such fraction multiplied
by the then Fair Market Value of one full Ordinary Share, together with any other stock or other securities and property (including
cash, where applicable) to which such Holder is entitled upon such exercise pursuant to Section 1 or otherwise.

 

2. Cashless Exercise.

 

(a) Commencing six months
after the Determination Date, provided such ordinary shares of the Company issuable here under are not subject to an effective
registration statement, upon delivering a Subscription Form, in lieu of making payment of the aggregate Purchase Price in cash
or by wire transfer, the Holder may elect instead to receive upon such exercise the “Net Number” of ordinary shares
determined according to the following formula (the “Cashless Exercise”):

 

Net Number = (A x B) –
(A x C)

B

 

Where for purposes of the foregoing formula:

 

		A =	the total number of Warrant Shares with respect to which
this Warrant is then being exercised.

 

		B =	the average of the last price (if traded on an exchange)
or closing bid price (if not traded on an exchange) of the Ordinary Shares for the five (5) Trading Days immediately prior to
(but not including) the Exercise Date as quoted by Bloomberg, LP, or Fair Market Value, whichever is less on the date of exercise
of the Warrant.

 

		C =	the Purchase Price then in effect for the applicable Warrant
Shares at the time of such exercise.

 

    	 	3	 

     

    

 

For purposes of Rule
144 promulgated under the 1933 Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise
transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed
to have commenced, on the date this Warrant was originally issued pursuant to the Convertible Loan Agreement.

 

3. Adjustment for Reorganization,
Consolidation, Merger, etc.

 

3.1. Fundamental Transaction. 
If, at any time while this Warrant is outstanding, (A) the Company  effects any merger or  consolidation  of
the Company with or into another entity, (B) the Company effects any sale of all or substantially all of its assets in
one or a series of related transactions,  (C) any tender offer or exchange offer (whether by
the Company or another entity) is completed pursuant to which holders of Ordinary Shares are permitted to tender or exchange
their shares for other securities, cash or property, (D) the Company consummates a stock purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with one or more persons or entities whereby such other persons or entities acquire more than the 50% of the outstanding Ordinary
Shares (not including any Ordinary Shares held by such other persons or entities making or party to, or associated or affiliated
with the other persons or entities making or party to, such stock purchase agreement or other business combination), (E) any “person”
or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act) is or shall become the
“beneficial owner” (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50% of the aggregate Ordinary
Shares of the Company, or (F) the Company effects any reclassification of the Ordinary Shares or any compulsory share exchange
pursuant to which the Ordinary Shares is effectively converted into or exchanged for other securities, cash
or property (in any such case, a “Fundamental  Transaction”), then, upon any subsequent exercise
of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior
to the occurrence of such Fundamental Transaction, at the option of the Holder, (a) upon exercise of this Warrant, the
number of Ordinary Shares of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and
any additional consideration (the “Alternate Consideration”) receivable upon or as a result of such reorganization,
reclassification, merger, consolidation or disposition of assets by a Holder of the number of Ordinary
Shares for which this Warrant is exercisable immediately prior to such event or (b) if the Company is acquired in
(1) a transaction where the consideration paid to the holders of the Ordinary Shares consists solely of cash, (2) a “Rule
13e-3 transaction” as defined in Rule 13e-3 under the 1934 Act, or (3) a transaction involving a person or entity not traded
on a national securities exchange, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market, cash equal to
the Black-Scholes Value.  For purposes of any such exercise, the determination of the Purchase Price shall
be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable
in respect of one Ordinary Shares in such Fundamental Transaction, and the Company shall apportion the
Purchase Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Ordinary Shares are given any choice as to the securities, cash or property to
be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction.  To the extent necessary to effectuate the foregoing provisions, any
successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent with
the foregoing provisions and evidencing the Holder’s right to exercise such warrant into Alternate
Consideration.  The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms
requiring any such successor or surviving entity to comply with the provisions of this Section 2.1 and insuring that
this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a
Fundamental Transaction. “Black-Scholes Value” shall be determined in accordance with the Black-Scholes Option Pricing
Model obtained from the “OV” function on Bloomberg L.P. using (i) a price per Ordinary Shares equal to the VWAP of
the Ordinary Shares for the Trading Day immediately preceding the date of consummation of the applicable Fundamental Transaction,
(ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant
as of the date of such request and (iii) an expected volatility equal to the 100 day volatility obtained from the HVT function
on Bloomberg L.P. determined as of the Trading Day immediately following the public announcement of the applicable Fundamental
Transaction.

 

    	 	4	 

     

    

 

3.2. Dissolution.
In the event of any dissolution of the Company following the transfer of all or substantially all of its properties or assets,
the Company, prior to such dissolution, shall at its expense deliver or cause to be delivered the stock and other securities and
property (including cash, where applicable) receivable by the Holder of the Warrants after the effective date of such dissolution
pursuant to this Section 3 to a bank or trust company (a “Trustee”) having its principal office in New York,
NY, as trustee for the Holder of the Warrants. Such property shall be delivered only upon payment of the Warrant exercise price.

 

3.3. Continuation
of Terms. Upon any reorganization, consolidation, merger or transfer (and any dissolution following any transfer) referred
to in this Section 3, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to the
Other Securities and property receivable on the exercise of this Warrant after the consummation of such reorganization, consolidation
or merger or the effective date of dissolution following any such transfer, as the case may be, and shall be binding upon the issuer
of any Other Securities, including, in the case of any such transfer, the person acquiring all or substantially all of the properties
or assets of the Company, whether or not such person shall have expressly assumed the terms of this Warrant as provided in Section 4.
In the event this Warrant does not continue in full force and effect after the consummation of the transaction described in this
Section 3, then only in such event will the Company’s securities and property (including cash, where applicable) receivable
by the Holder of the Warrants be delivered to the Trustee as contemplated by Section 3.2.

 

4. Extraordinary
Events Regarding Ordinary Shares. In the event that the Company shall (a) issue additional Ordinary Shares as a dividend
or other distribution on outstanding Ordinary Shares, (b) subdivide its outstanding Ordinary Shares, or (c) combine its
outstanding Ordinary Shares into a smaller number of Ordinary Shares, then, in each such event, the Purchase Price shall, simultaneously
with the happening of such event, be adjusted by multiplying the then Purchase Price by a fraction, the numerator of which shall
be the number of Ordinary Shares outstanding immediately prior to such event and the denominator of which shall be the number of
Ordinary Shares outstanding immediately after such event, and the product so obtained shall thereafter be the Purchase Price then
in effect. The Purchase Price, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event
or events described herein in this Section 4. The number of Ordinary Shares that the Holder of this Warrant shall thereafter,
on the exercise hereof, be entitled to receive shall be adjusted to a number determined by multiplying the number of Ordinary Shares
that would otherwise be issuable on such exercise by a fraction of which (a) the numerator is the Purchase Price that would otherwise
be in effect, and (b) the denominator is the Purchase Price in effect on the date of such exercise.

 

5. Certificate as
to Adjustments. In each case of any adjustment or readjustment in the Ordinary Shares (or Other Securities) issuable on the
exercise of the Warrants, the Company at its expense will promptly cause its Chief Financial Officer or other appropriate designee
to compute such adjustment or readjustment in accordance with the terms of the Warrant and prepare a certificate setting forth
such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based, including
a statement of (a) the consideration received or receivable by the Company for any additional Ordinary Shares (or Other Securities)
issued or sold or deemed to have been issued or sold, (b) the number of Ordinary Shares (or Other Securities) outstanding
or deemed to be outstanding, and (c) the Purchase Price and the number of Ordinary Shares to be received upon exercise of
this Warrant, in effect immediately prior to such adjustment or readjustment and as adjusted or readjusted as provided in this
Warrant. The Company will forthwith mail a copy of each such certificate to the Holder of the Warrant and any Warrant Agent of
the Company (appointed pursuant to Section 10 hereof).

 

    	 	5	 

     

    

 

6. Reservation of
Stock, etc. Issuable on Exercise of Warrant; Financial Statements. The Company will at all times reserve and keep available,
solely for issuance and delivery on the exercise of the Warrants, all Ordinary Shares (or Other Securities) from time to time issuable
on the exercise of the Warrant. This Warrant entitles the Holder hereof to receive copies of all financial and other information
distributed or required to be distributed to the holders of the Company’s Ordinary Shares.

 

7. Assignment; Exchange
of Warrant. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby, may be transferred
by any registered holder hereof (a “Transferor”). On the surrender for exchange of this Warrant, with the Transferor’s
endorsement in the form of Exhibit B attached hereto (the “Transferor Endorsement Form”) and together with
an opinion of counsel reasonably satisfactory to the Company that the transfer of this Warrant will be in compliance with applicable
securities laws, the Company will issue and deliver to or on the order of the Transferor thereof a new Warrant or Warrants of like
tenor, in the name of the Transferor and/or the transferee(s) specified in such Transferor Endorsement Form (each a “Transferee”),
calling in the aggregate on the face or faces thereof for the number of Ordinary Shares called for on the face or faces of the
Warrant so surrendered by the Transferor.

 

8. Replacement of
Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this
Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement or security
reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation
of this Warrant, the Company at its expense, twice only, will execute and deliver, in lieu thereof, a new Warrant of like tenor.

 

9. Maximum Exercise.
The Holder shall not be entitled to exercise this Warrant on an exercise date in connection with that number of Ordinary Shares
which would be in excess of the sum of (i) the number of Ordinary Shares beneficially owned by the Holder and its affiliates
on an exercise date, and (ii) the number of Ordinary Shares issuable upon the exercise of this Warrant with respect to which
the determination of this limitation is being made on an exercise date, which would result in beneficial ownership by the Holder
and its affiliates of more than 4.99% of the outstanding Ordinary Shares on such date; provided that the restrictions on exercise
set forth in this Section 9 shall not apply in event of completion of a Fundamental Transaction. For the purposes of the immediately
preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities 1934
Act, and Rule 13d-3 thereunder. Subject to the foregoing, the Holder shall not be limited to aggregate exercises which would result
in the issuance of more than 4.99%. The restriction described in this paragraph may be waived, in whole or in part, upon sixty-one
(61) days prior notice from the Holder to the Company to increase such percentage to up to 9.99%, but not in excess of 9.99%. The
Holder may decide whether to exercise this Warrant to achieve an actual 4.99% or up to 9.99% ownership position as described above,
but not in excess of 9.99%.

 

10. Warrant Agent.
The Company may, by written notice to the Holder of the Warrant, appoint an agent (a “Warrant Agent”) for the purpose
of issuing Ordinary Shares (or Other Securities) on the exercise of this Warrant pursuant to Section 1, exchanging this Warrant
pursuant to Section 7, and replacing this Warrant pursuant to Section 8, or any of the foregoing, and thereafter any
such issuance, exchange or replacement, as the case may be, shall be made at such office by such Warrant Agent.

 

    	 	6	 

     

    

 

11. Transfer on
the Company’s Books. Until this Warrant is transferred on the books of the Company, the Company may treat the registered holder
hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.

 

12. Notices.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed
effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine,
at the address or number designated below (if delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered other than on a business day during normal business
hours where such notice is to be received), (b) receipt, when sent by electronic mail (provided that the electronic mail transmission
is not returned in error or the sender is not otherwise notified of any error in transmission or (c) on the second business day
following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such
mailing, whichever shall first occur. The addresses for such communications shall be: if to the Company, to: Todos Medical Ltd.,
1 Hamada, Rehovot, Israel, Attn: Chief Financial Officer, with a copy by telecopier only to: Steve Kronengold, SRK Law Offices,
Oppenheimer 7, Rehovot, Israel, Fax: +972-8-936-6000, and (ii) if to the Holder, to the address and telecopier number listed in
the records of the Company, or such other address as such party may designate by notice hereunder.

 

13. Law Governing
This Warrant. This Warrant shall be governed by and construed in accordance with the laws of the State of New York without
regard to principles of conflicts of laws. Any dispute, claim or controversy involving this Warrant shall be settled through binding
arbitration in accordance with the Commercial Rules of the American Arbitration Association, in Manhattan, New York. The parties
to this Warrant hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not
assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Company and Holder waive
trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney’s fees and costs.
In the event that any provision of this Warrant or any other agreement delivered in connection herewith is invalid or unenforceable
under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict
therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid
or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party
hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in
connection with this Agreement by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence
of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any other manner permitted by law.

 

    	 	7	 

     

    

 

IN WITNESS WHEREOF, the
Company has executed this Warrant as of the date first written above.

 

	 	TODOS MEDICAL LTD.
	 	 	 
	 	By:	 
	 	 	Name:

 

    	 	8	 

     

    

 

Exhibit A

 

FORM OF SUBSCRIPTION

(to be signed only on exercise of Warrant)

 

TO: TODOS MEDICAL LTD.

 

The undersigned, pursuant to the provisions
set forth in the attached Warrant (No.____), hereby irrevocably elects to purchase (check applicable box):

 

☐ ________ Ordinary Shares covered by
such Warrant.

 

☐ ________ the maximum number of Ordinary
Shares covered by such Warrant pursuant to the cashless exercise procedure set forth in Section 2.

 

The undersigned herewith makes payment
of the full purchase price for such shares at the price per share provided for in such Warrant, which is $___________. Such payment
takes the form of (check applicable box or boxes)

 

☐ $__________ in lawful money of the
United States and/or

 

☐ the cancellation of such portion of
the attached Warrant as is exercisable for a total of _______ Ordinary Shares (using a Fair Market Value of $_______ per share
for purposes of this calculation); and/ or

 

☐ the cancellation of such number of
Ordinary Shares as is necessary, in accordance with the formula set forth in Section 2, to exercise this Warrant with respect
to the maximum number of Ordinary Shares purchasable pursuant to the cashless exercise procedure set forth in Section 2.

 

The undersigned requests that the certificates
for such shares be issued in the name of, and delivered to ____________________________________________ whose address
is ______________________________________________.

 

The undersigned represents and warrants
that all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant
to registration of the Ordinary Shares under the Securities Act of 1933, as amended (the “Securities Act”), or pursuant
to an exemption from registration under the Securities Act.

 

	Dated:___________________	 	
         

        (Signature must conform to name of holder as specified on the
        face of the Warrant)

         

         

         

        (Address)

 

    	 	9	 

     

    

 

Exhibit B

 

FORM OF TRANSFER OR ENDORSEMENT

(To be signed only on transfer of Warrant)

 

For value received, the
undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading “Transferees” the right
represented by the within Warrant to purchase the percentage and number of Ordinary Shares of TODOS MEDICAL LTD. to which the within
Warrant relates specified under the headings “Percentage Transferred” and “Number Transferred,” respectively,
opposite the name(s) of such person(s) and appoints each such person Attorney to transfer its respective right on the books of
TODOS MEDICAL LTD. with full power of substitution in the premises.

  

	Transferees	 	Percentage Transferred	 	Number Transferred
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

	Dated:  ______________, ___________	 	 
	 	 	(Signature must conform to name of holder as specified on the face of the warrant)
	 	 	 
	Signed in the presence of:	 	 
	 	 	 
	(Name)	 	 
	 	 	(address)
	 	 	 
	ACCEPTED AND AGREED:	 	 
	[TRANSFEREE]	 	 
	 	 	(address)
	 	 	 
	(Name)	 	 

 

    	 	10Exhibit 4.4

 

SHARE PURCHASE AND ASSIGNMENT OF LICENSE
AGREEMENT

 

THIS SHARE PURCHASE
AND ASSIGNMENT OF LICENSE AGREEMENT (the “Agreement”) is made and entered into as of this 27 day of February,
2019 (the “Effective Date”), by and among (1) Todos Medical Ltd., an Israeli company, with an address
at Rechov HaMada 1, Rehovot 7670301, Israel, (“Todos”); (2) Amarantus Bioscience Holdings, Inc., a Nevada
corporation, with an address at 45 Wall St., Suite 920, New York, NY 10005 (“Amarantus”); and (3) Breakthrough
Diagnostics, Inc., a Nevada corporation, with an address at 45 Wall St., Suite 920, New York, NY 10005 (the “Subsidiary”).
Todos, Amarantus, and Breakthrough shall be referred to collectively herein as the “Parties,” and each separately
as a “Party”.

 

WHEREAS, Amarantus
has entered into an amended and restated exclusive license agreement with the University of Leipzig (the “License Agreement”),
attached hereto as Exhibit A, pursuant to which Amarantus has obtained an exclusive license to develop and commercialize
the LymPro Test®, an immune-based neurodiagnostic blood test for the detection of Alzheimer’s disease (the “License”);
and

 

WHEREAS, the
Subsidiary is a wholly-owned subsidiary of Amarantus; and

 

WHEREAS, Todos
is interested in issuing such number of Ordinary Shares of Todos, par value NIS 0.01 each, representing 19.99% of its issued and
outstanding shares, to Amarantus, in exchange for Amarantus transferring to Todos 19.99% of the Subsidiary and assigning the License
Agreement to the Subsidiary;

 

NOW THEREFORE,
in consideration of the premises and the mutual promises herein made, and in consideration of the representations, warranties,
and covenants herein contained, and intending to be legally bound hereby, the Parties agree as follows:

 

1. The Transaction.

 

1.1 Subject to the
terms and conditions set forth herein, (a) Todos shall issue to Amarantus fourteen million four hundred seventy-two thousand, seven
hundred forty-six (14,472,736) Ordinary Shares of Todos, par value NIS 0.01 each, (the “Todos Shares”), representing
post-issuance 19.99% of the issued and outstanding shares of Todos, and (b) Amarantus shall transfer to Todos nineteen thousand
nine hundred ninety (19,990) shares of common stock of the Subsidiary, par value $0.001 each, (the “Subsidiary Shares”),
representing 19.99% of the issued and outstanding shares of the Subsidiary (the “Share Transaction”). The Share
Transaction shall be consummated at the closing as set forth in Section 2 below.

 

1.2 Subject to the
terms and conditions set forth herein, Amarantus shall assign, transfer, and contribute to the Subsidiary all of Amarantus’s
LymPro technology assets, including the License Agreement and the License, (the “Lympro Technology”), all as
more fully detailed in Exhibit B attached hereto, (the “Assignment Transaction”, and together with the
Share Transaction, the “Transaction”). The Assignment Transaction shall be consummated at the closing as set
forth in Section 2 below.

 

    

     

    

  

2. Closing

 

2.1 The closing of
the Transaction (the “Closing”) shall take place within three (3) business days of the Effective Date, or on such other
date as agreed upon by the Parties (the “Closing Date”).

 

2.2 At the Closing,
the following transactions shall occur, which transactions shall be deemed to take place simultaneously and no transaction shall
be deemed to have been completed or any document delivered until all such transactions have been completed and all required documents
delivered:

 

(a) Todos shall issue
and deliver the Todos Shares to Amarantus;

 

(b) Amarantus shall transfer
the Subsidiary Shares to Todos and deliver to Todos a Share Transfer Deed, substantially in the form attached hereto as Exhibit
C, duly executed by Amarantus, evidencing the transfer of the Subsidiary Shares to Todos;

 

(c) Amarantus shall assign,
transfer, and contribute the LymPro Technology to the Subsidiary, and deliver to Todos a copy of an Assignment and Assumption Agreement,
substantially in the form attached hereto as Exhibit D, duly executed by Amarantus and the Subsidiary, evidencing the assignment
of the LymPro Technology to the Subsidiary.

 

2.3 To the extent that the consent of any
person is required for the assignment of the LymPro Technology to the Subsidiary, Amarantus shall (at its own expense) have obtained
from the applicable persons the required consents on or prior to the Closing Date.

 

3. Information
on Todos

 

Amarantus has been
furnished with or has had access at the EDGAR Website of the SEC to the Todos Form 20-F filed on May 15, 2018 for the fiscal year
ended December 31, 2017 and the financial statements included therein for the year ended December 31, 2017, together with all subsequent
filings made with the SEC available at the EDGAR website (“Reports”). In addition, Amarantus may have received in writing
from Todos such other information concerning its operations, financial condition and other matters as Amarantus has requested in
writing, identified thereon as “Other Written Information” and considered all factors such Investor deems material in
deciding on the advisability of entering into this Agreement.

 

4. Representations and Warranties of
Todos.

 

Todos hereby represents
and warrants to Amarantus as follows:

 

4.1 Organization
and Qualification. Todos is a corporation duly organized, validly existing and in good standing under the laws of the State
of Israel and has the requisite corporate power to own its properties and to carry on its business as it is now being conducted.

 

    2

     

    

  

4.2 Authorization,
Enforceability. (i) Todos has the requisite corporate power and authority to enter into this Agreement and to perform its obligations
hereunder in accordance with the terms hereof, (ii) the execution and delivery of this Agreement by Todos and the consummation
by it of the transactions contemplated hereby have been duly authorized by Todos’s Board of Directors and further consent
or authorization of Todos by its Board of Directors is not required; and (iii) upon the execution and delivery of this Agreement
by Todos, this Agreement will constitute valid and binding obligations of Todos enforceable against Todos in accordance with their
terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation
or similar laws relating to, or affecting generally the enforcement of creditors’ rights and remedies or by other equitable
principles of general application.

 

4.3 Share Capital.
The authorized share capital of Todos consists of 1,000,000,000 ordinary shares, par value NIS 0.01 per ordinary share, of which
72,399,932 ordinary shares are issued and outstanding.

 

4.4 Issuance of
the Todos Shares. The Todos Shares to be issued, sold and delivered by Todos hereunder, when so issued, sold and delivered,
will be duly and validly issued, fully paid and nonassessable and will be issued in reliance upon applicable exemptions from the
registration and qualification provisions of all applicable securities laws of the United States and each state whose securities
laws may be applicable thereto. All Todos Shares will be issued free of any preemptive or similar right and free and clear of any
claim, lien, security interest or other encumbrance. Assuming the accuracy of Amarantus’s representations and warranties
hereunder, the issuance to Amarantus of the Todos Shares will be exempt from the registration requirements of the Securities Act
and will be made in reliance upon applicable exemptions from the registration and qualification provisions of all applicable state
securities laws.

 

4.5
No Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government
agency, self-regulatory organization or body pending against or affecting Todos, its ordinary shares, wherein an unfavorable decision,
ruling or finding would have a material adverse effect on Todos.

 

4.6
Compliance with Applicable Laws. The operations of Todos are and have been conducted at all times in compliance applicable
laws and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
Todos with respect to applicable laws is pending or, to the knowledge of Todos, threatened.

 

4.7 Listing and Maintenance
Requirements. Todos’s ordinary shares are registered pursuant to Section 12(b) or 12(g) or (15(d) of the Exchange Act,
and Todos has taken no action designed to terminate, or which to its knowledge is likely to have the effect of, terminating the
registration of the ordinary shares under the Exchange Act nor has Todos received any notification that the SEC is contemplating
terminating such registration. Todos has not, in the 12 months preceding the date hereof, received notice from the market on which
its ordinary shares are listed or quoted to the effect that Todos is not in compliance with the listing or maintenance requirements
of such market. Todos is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance
with all such listing and maintenance requirements.

 

    3

     

    

   

5. Representations and Warranties of
Amarantus.

 

Amarantus hereby represents,
warrants, acknowledges, understands and agrees (as the case may be) to the following, and acknowledges that Todos’s reliance on
exemption from registration pursuant to a registration statement under the Securities Act of 1933, as amended (the “Securities
Act”) is predicated upon the representations of Amarantus set forth herein:

 

5.1 Organization
and Qualification. Amarantus is a corporation duly organized, validly existing and in good standing under the laws of the State
of Nevada and has the requisite corporate power to own its properties and to carry on its business as it is now being conducted.

 

5.2 Authorization,
Enforceability. (i) Amarantus has the requisite corporate power and authority to enter into this Agreement and to perform its
obligations hereunder in accordance with the terms hereof, (ii) the execution and delivery of this Agreement by Amarantus and the
consummation by it of the transactions contemplated hereby have been duly authorized by Amarantus’s Board of Directors and
further consent or authorization of Amarantus by its Board of Directors is not required; and (iii) upon the execution and delivery
of this Agreement by Amarantus, this Agreement will constitute valid and binding obligations of Amarantus enforceable against Amarantus
in accordance with their terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of creditors’ rights and remedies
or by other equitable principles of general application.

 

5.3 The LymPro Technology
Amarantus owns or possesses valid and enforceable licenses, free and clear of any lien, pledge, claim, charge, or encumbrance to
the LymPro Technology, without any conflict with, or infringement of, the rights of others. Amarantus has the right and power to
assign and transfer the LymPro Technology to the Subsidiary.

 

5.4 No Litigation.
There is no civil, criminal or administrative suit, action, proceeding, arbitration, investigation, review or inquiry pending or,
to Amarantus’s knowledge, threatened against or affecting Amarantus with respect to the LymPro technology, nor is there any
judgment, decree, injunction, rule or order of any governmental authority or arbitrator outstanding against or affecting Amarantus
with respect to the Lympro Technology. No event has occurred or circumstance exists which could reasonably be expected to give
rise to or serve as a valid basis for the commencement of any litigation or claim by or against Amarantus with respect to the LymPro
Technology.

 

5.5 The Todos Shares
Are Not Registered. Amarantus hereby acknowledges that the Todos Shares will not be issued by Todos pursuant to a registration
statement under the Securities Act, and therefore Amarantus may be required to hold the Todos Shares for an indeterminate period.
The Todos Shares are issued pursuant hereto in reliance upon a specific exemption from the registration requirement of the Securities
Act which depends, in part, upon the accuracy of the representations, warranties, and agreements of Amarantus set forth in this
Agreement. The Todos Shares constitute “restricted securities” as defined in Rule 144 under the Securities Act and
may be resold without registration under the Securities Act only in certain limited circumstances.

 

5.6 Investment Intent.
Amarantus is acquiring the Todos Shares for Amarantus’s own account as principal, not as a nominee or agent, for investment
purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof, in whole or in part, which resale,
distribution or fractionalization would violate the Securities Act. Amarantus agrees that a legend to the foregoing effect may
be placed upon any and all certificates issued representing the Todos Shares. Further, Amarantus does not have any contract, undertaking,
agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with
respect to the Todos Shares, for which Amarantus is purchasing. Amarantus acknowledges that he has been afforded the opportunity
to ask questions of, and to obtain any information from, Todos and the Board of Directors as its deems necessary to determine the
suitability and advisability of, and the merits and risk of, investing in Todos pursuant hereto.

 

    4

     

    

  

5.7 Risk. Amarantus
has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the
purchase of the Todos Shares. Amarantus is aware that: (i) investment in Todos involves a high degree of risk, may result in a
lack liquidity, and places substantial restrictions on transferability of interest; and (ii) no Federal or state agency has made
any finding or determination as to the fairness for investment by the public, nor has made any recommendation or endorsement, of
the Todos Shares.

 

5.8 Financial Ability.
Amarantus has sufficient financial resources available to support the loss of all or a portion of Investor’s investment in
Todos, has no need for liquidity in the investment in Todos, is able to hold the Todos Shares for an indefinite period of time,
and is able to bear the economic risk of the investment. Amarantus is sophisticated and experienced in investment matters, and,
as a result, is in a position to evaluate an investment in Todos.

 

6. Representations and Warranties Relating
to the Subsidiary

 

Amarantus and the Subsidiary
hereby represent and warrant to Todos as follows:

 

6.1 Organization
and Qualification. The Subsidiary is a corporation duly organized, validly existing and in good standing under the laws of
the State of Nevada and has the requisite corporate power to own its properties and to carry on its business as it is now being
conducted.

 

6.2 Authorization,
Enforceability. (i) The Subsidiary has the requisite corporate power and authority to enter into this Agreement and to perform
its obligations hereunder in accordance with the terms hereof, (ii) the execution and delivery of this Agreement by the Subsidiary
and the consummation by it of the transactions contemplated hereby have been duly authorized by the Subsidiary’s Board of
Directors and further consent or authorization of the Subsidiary by its Board of Directors is not required; and (iii) upon the
execution and delivery of this Agreement by the Subsidiary, this Agreement will constitute valid and binding obligations of the
Subsidiary enforceable against the Subsidiary in accordance with their terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement
of creditors’ rights and remedies or by other equitable principles of general application.

 

6.3 Subsidiary Share
Capital. The authorized share capital of the Subsidiary consists of one million (1,000,000) shares of common stock, par value
$0.001 per share, of which one hundred thousand (100,000) shares of common stock are issued and outstanding (the “Subsidiary
Issued Shares”). All of the Subsidiary Issued Shares are lawfully owned by Amarantus. All voting rights in the Subsidiary
are vested exclusively in the Subsidiary Issue Shares, and all of the Subsidiary Issued Shares are validly issued in compliance
with applicable laws, fully paid and non-assessable. The Subsidiary does not have outstanding any bonds, debentures, notes or other
obligations or securities the holders of which have the right to vote (or that are convertible into or exercisable for securities
having the right to vote) with the shareholders of the Subsidiary

 

    5

     

    

  

6.4 No Rights to
Acquire Shares. No subscription, warrant, option, convertible security or other right (contingent or otherwise) to purchase
or acquire from the Subsidiary any equity interest of the Subsidiary is authorized or outstanding. The Subsidiary has no obligation
(contingent or otherwise) to issue any subscription, warrant, option, convertible security or other such right, or to issue or
distribute to holders of any equity interest any evidences of indebtedness or assets of the Subsidiary. The Subsidiary has no obligation
(contingent or otherwise) to purchase, redeem or otherwise acquire any of its equity interests or any interest therein or to pay
any dividend or to make any other distribution in respect thereof. There are no outstanding or authorized stock appreciation, phantom
stock or similar rights with respect to the Subsidiary.

 

6.5 The Subsidiary
Shares. The Subsidiary Shares to be transferred by Amarantus to Todos hereunder, when so transferred and delivered, will be
duly and validly issued, fully paid and nonassessable and will be issued free of any preemptive or similar right and free and clear
of any claim, lien, security interest or other encumbrance. Except for Todos’s rights under this Agreement, no person has
any written or oral agreement, option, understanding or commitment or any right or privilege (whether by law, contractual or otherwise)
for the purchase or acquisition from Amarantus of any equity interests of the Subsidiary.

 

6.6 No Obligations or Liabilities.
Prior to the Closing, the Subsidiary owns no assets, has no liabilities, has no employees, has no consultants, has no properties,
and has conducted no business. Prior to the Closing, the Subsidiary has no outstanding indebtedness or liabilities.

 

6.7 No Litigation.
There is no civil, criminal or administrative suit, action, proceeding, arbitration, investigation, review or inquiry pending or,
to Amarantus’s knowledge, threatened against or affecting the Subsidiary, nor is there any judgment, decree, injunction,
rule or order of any governmental authority or arbitrator outstanding against or affecting the Subsidiary. No event has occurred
or circumstance exists which could reasonably be expected to give rise to or serve as a valid basis for the commencement of any
litigation or claim by or against the Subsidiary.

 

7. Management of the Subsidiary

 

7.1 Following the Closing,
the Board of Directors of the Subsidiary will consist of three (3) members, one of whom will be appointed by Amarantus and one
of whom by Todos, and the third member will be appointed by the two directors.

 

7.2 Amarantus and Todos
are hereby forming a Management Committee to advise the Subsidiary on its activities. The Management Committee will consist of
six (6) members, with four (4) members to be appointed by Amarantus (initially, Gerald Commissiong, Dr. Elise Brownell, Dr. Michael
Ropacki and Dr. Paula Trzepacz) and two (2) members to be appointed by Todos (Dr. Herman Weiss, and up to one other member. The
Management Committee will meet regularly.

 

7.3 Upon the Closing,
Gerald Commissiong shall be the only officer in the Subsidiary, subject to the acquisition director’s & officer’s
insurance, which will obtained promptly, and will conduct operations subject to direction by the Management Committee. Responsibility
for the appointments of other specified officers will be made by the Subsidiary’s management.

 

    6

     

    

  

8. Veto Rights

 

Following the Closing,
the Subsidiary may not take any of the following actions without the express written consent of Todos or the Director appointed
by Todos to the Board of the Subsidiary:

 

(a) amending the corporate/governing
documents of the Subsidiary;

 

(b) the authorization
or issuance of any shares or other rights or securities convertible into or exchangeable for shares;

 

(c) the merger, consolidation,
acquisition or other reorganization of the Subsidiary, or the sale of all or substantially all of the Subsidiary’s assets
or shares;

 

(d) the increase
in the number of the Subsidiary’s Directors above five;

 

(e) the declaration
or payment of any dividend;

 

(f) any transaction with
any shareholder, director or officer of the Subsidiary or with an affiliated company or a direct relative of any shareholder, director
or officer of the Subsidiary;

 

(g) the liquidation,
dissolution or winding up of the Subsidiary or cessation of the Subsidiary’s activities;

 

(h) material changes
to the Subsidiary’s annual business plan; and

 

(i) expenditures outside
of the Subsidiary’s annual operating budget.

 

9. Non-Compete

 

Each of Todos and Amarantus
agrees that it will not directly or indirectly (a) compete with the Subsidiary, (b) invest in, finance, or provide services to
a competing business, (c) solicit customers or employees away from the Subsidiary, (d) disparage the Subsidiary or its reputation,
or (e) use trade names similar to the Subsidiary’s name. This Section 9 will survive any termination of this Agreement.

 

10. Board of Directors of Todos

 

Following the Closing
and until the next shareholders meeting of Todos, Amarantus shall be entitled to appoint one member to the Board of Directors of
Todos.

 

    7

     

    

  

11. Option to Acquire the Subsidiary

 

11.1 For a period of
sixty (60) days following the Closing, Todos shall have the option to acquire the remaining 80.01% of the Subsidiary held by Amarantus
in exchange for the issuance to Amarantus of Ordinary Shares of Todos representing an additional thirty percent (30%) of Todos
(the “Option”), such that upon consummation of the Option transaction Todos shall own 100% of the Subsidiary
and Amarantus shall own 49.99% of Todos.

 

11.2 Todos shall notify
Amarantus in writing of its intention to exercise the Option, and the closing of the Option transaction shall take place within
fourteen (14) days of Amarantus’ receipt of such notice.

 

12. Miscellaneous.

 

12.1 Further Assurances.
From and after the date of this Agreement, each Party shall execute and deliver such instruments, documents and other writings
as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.

 

12.2 Governing Law;
Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of Israel, without regard to the
conflict of laws provisions thereof. The parties hereto irrevocably submit to the jurisdiction of the appropriate courts
of Israel with respect to any suit, action or proceeding pertaining to this Agreement.

 

12.3 Successors
and Assigns; Assignment. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of,
and be binding upon, the successors, assigns, heirs, executors, and administrators of the Parties hereto. None of the rights, privileges,
or obligations set forth in, arising under, or created by this Agreement may be assigned or transferred without the prior consent
in writing of each Party to this Agreement.

 

12.4 Entire Agreement;
Amendment and Waiver. This Agreement constitutes the full and entire understanding and agreement between the Parties with regard
to the subject matters hereof and thereof. Only upon the written consent of Todos and Amarantus may any term of this Agreement
be amended or performance of any term hereof be waived (either prospectively or retroactively and either generally or in a particular
instance).

 

12.5 Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original and enforceable against the Party actually
executing such counterpart, and all of which together shall constitute one and the same instrument.

 

12.6 Confidentiality.
The Parties hereto agree that any information obtained from, or on behalf of the Parties in furtherance of or pursuant to this
Agreement will be considered “confidential,” will be used solely for the purpose set out in this Agreement, and will
not be used for any other purpose or disclosed to any person without the prior written consent of the Party providing such confidential
information.

 

    8

     

    

  

IN WITNESS WHEREOF,
the Parties have executed this Agreement on the date set forth above.

 

	Todos Medical Ltd.	 	Amarantus Bioscience Holdings, Inc.
	 	 	 	 
	/s/ Herman Weiss	 	/s/ Gerald Commissiong
	Name:	Herman Weiss, MD	 	Name:	Gerald Commissiong
	Title:	CEO	 	Title:	President and CEO
	Date:		 	Date:	 
	 	 	 	 	 
	 	 	 	Breakthrough Diagnostics, Inc.
	 	 	 	 	 
	 	 	 	/s/ Gerald Commissiong
	 	 	 	Name:	Gerald Commissiong
	 	 	 	Title:	Interim CEO
	 	 	 	Date:	 

 

List of Exhibits:

 

	Exhibit A:	License Agreement with the University of Leipzig
	Exhibit B:	LymPro Technology
	Exhibit C:	Form of Share Transfer Deed
	Exhibit D:	Form of Assignment and Assumption Agreement

 

    9

     

    

 

EXHIBIT A

 

AMENDED AND RESTATED LICENSE AGREEMENT
WITH THE UNIVERSITY OF LEIPZIG 

 

    10

     

    

  

EXHIBIT B

 

LYMPRO TECHNOLOGY 

 

1. Amended and Restated Exclusive License
Agreement with the University of Leipzig dated November 7, 2018 (the “License Agreement”)

 

2. The exclusive license to the Patent Rights
and Related Materials pursuant to the License Agreement (the “License”)

 

3. Sponsored Research Agreement with the University
of Leipzig dated November 7, 2018.

 

4. The LymPro Test, including the registered
trademark.

 

5.
MSPrecise, including 

o US Patent Application 15/546,171

o Chinese Patent Application
No. 201480075681.6

 

6. NeuroPro, including

o
US Patent 9,547,012 

 

7. All (a) copyrights (including software,
databases, and related documentation), trademarks, service marks, logos, trade or business names, and all registrations of any
of the foregoing, and all applications for registration thereof, and all goodwill associated therewith; (b) patents and patent
applications, including without limitation continuations, continuations-in-part, divisionals, provisionals, reexaminations, reissue
applications, and renewals, and (c) trade secrets, formulations, formulas, recipes, inventions, processes, know-how, and confidential
information, relating to the foregoing.

 

    11

     

    

  

EXHIBIT C

 

FORM OF SHARE TRANSFER DEED 

 

SHARE TRANSFER DEED

 

For value received, the undersigned, Amarantus
Bioscience Holdings, Inc. (the “Transferor”), does hereby irrevocably sell, assign, transfer, convey, and
deliver to Todos Medical Ltd. (the “Acquiror”), Nineteen Thousand Nine Hundred Ninety (19,990) shares of
common stock, par value $0.001 each, of Breakthrough Diagnostics, Inc., a Nevada corporation, (the “Shares”
and the “Company”, respectively), standing in the name of the Transferor on the books of the Company.

 

Dated: February 27, 2019

 

	The Transferor	 	The Acquiror
	 	 	 
		 	 
	Amarantus Bioscience Holdings, Inc.	 	Todos Medical Ltd.
	By:			By:	 
	Title:	          		Title:	 

 

    12

     

    

  

EXHIBIT D

 

FORM OF ASSIGNMENT AND ASSUMPTION AGREEMENT

 

ASSIGNMENT AND ASSUMPTION AGREEMENT

 

THIS ASSIGNMENT AND
ASSUMPTION AGREEMENT (this “Agreement”) is entered into as of February __, 2019, by and between Amarantus
Bioscience Holdings, Inc., a Nevada corporation (“Assignor”), and Breakthrough Diagnostics, Inc.,
a Nevada corporation (“Assignee”).

 

WHEREAS, Assignor
and Assignee are parties to that certain Share Purchase and Assignment of License Agreement, dated on or about the date hereof
(the “Purchase Agreement”); and

 

WHEREAS, pursuant
to the Purchase Agreement, Assignor has agreed to assign to Assignee all of Assignor’s right, title, and interest in and
to the LymPro technology assets listed on Schedule 1 to this Agreement (the “LymPro Technology”);

 

NOW, THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.
Assignment.
Assignor hereby transfers, assigns, and delivers to Assignee, and Assignee hereby accepts and acquires from Assignor, all of Assignor’s
right, title and interest in and to the LymPro Technology, including all common law rights and goodwill associated therewith, free
and clear of all encumbrances.

 

2. Further
Assurances. Without further consideration, Assignor will promptly take all such further actions, and execute and deliver
to Assignee all such further documents and instruments which Assignee may reasonably request for the purpose of carrying out the
intent of this Agreement and evidencing or better effecting the assignment contained herein.

 

3. Recordation.
Assignor hereby authorizes the United States Patent and Trademark Office, and other corresponding officials of other jurisdictions,
as appropriate, to record this instrument and to record Assignee as the owner of the LymPro Technology with respect to any such
intellectual property that is currently registered in Assignor’s name.

 

4. Heirs,
Successors and Assigns. This Agreement shall bind and inure to the benefit of the parties hereto and to their respective
successors and assigns.

 

5. Governing
Law. This Agreement shall be governed by, and shall be construed according to, the laws of the State of New York, without
regard to conflict of law rules.

 

6. Counterparts.
This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original
for all purposes, and all such counterparts shall together constitute but one and the same instrument.

 

7. The Purchase
Agreement. This Agreement is subject to the terms of the Purchase Agreement, and nothing contained in this Agreement shall
be deemed to modify, alter, or amend the terms and provisions of the Purchase Agreement.

 

8. Entire
Agreement. This Agreement and the Purchase Agreement constitute the entire agreement between the parties and supersede
any prior understandings, agreements, or representations by or between the parties, written or oral, that may have related in any
way to the subject matter hereof.

 

    13

     

    

   

IN WITNESS HEREOF,
the parties have executed this Agreement as of the date set forth above.

 

	Amarantus Bioscience Holdings, Inc.	 	Breakthrough Diagnostics, Inc.
	 	 	 
	 	 	 
	Name:	 	Name:
	Title:	 	Title:
	Date:	 	Date:

 

    14

     

    

 

SCHEDULE 1

 

LYMPRO TECHNOLOGY

 

1. Amended and Restated Exclusive License
Agreement with the University of Leipzig dated November 7, 2018 (the “License Agreement”)

 

2. The exclusive license to the Patent Rights
and Related Materials pursuant to the License Agreement (the “License”)

 

3. Sponsored Research Agreement with the University
of Leipzig dated November 7, 2018.

 

4. The LymPro Test, including the registered
trademark.

 

5. MSPrecise,
including

o US Patent Application
15/546,171

o Chinese Patent Application
No. 201480075681.6

 

6. NeuroPro, including

o US Patent 9,547,012

 

7. All (a) copyrights (including software,
databases, and related documentation), trademarks, service marks, logos, trade or business names, and all registrations of any
of the foregoing, and all applications for registration thereof, and all goodwill associated therewith; (b) patents and patent
applications, including without limitation continuations, continuations-in-part, divisionals, provisionals, reexaminations, reissue
applications, and renewals, and (c) trade secrets, formulations, formulas, recipes, inventions, processes, know-how, and confidential
information, relating to the foregoing.

 

 

15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]